Rich Carney, CFA

Research Analyst
Rich Carney, CFA | Janus Henderson Investors

Rich Carney is a Research Analyst at Janus Henderson Investors primarily focused on companies in the Health Care sector. Prior to joining Janus in 2015, Rich was a portfolio manager for Gerlach, Way, Scarth & Associates, where he managed high-net-worth portfolios. Previously, he was a partner and portfolio manager/analyst at Platte River Capital responsible for co-managing an equity portfolio as the lead analyst in the health care and financial services sectors. Rich’s experience also includes serving as a research analyst at The Boston Company, Silvergate Capital Management, and Invesco.

Rich received his bachelor of arts degree in economics from Rutgers University and a master of science degree in finance from Northeastern University. He holds the Chartered Financial Analyst designation and has 26 years of financial industry experience.

Articles Written

US Affordable Care Act: “Reports of my death are greatly exaggerated”

US Affordable Care Act: “Reports of my death are greatly exaggerated”

With the U.S. Supreme Court set to hear arguments about the constitutionality of the Affordable Care Act (ACA) on 10 November, the death of Justice Ruth Bader Ginsburg has raised doubts about the law’s future and led stocks of hospitals and insurance providers to sell off. But Portfolio Manager Andy Acker and Research Analyst Rich Carney say the reaction may be overdone.

COVID-19: Understanding the science & investment implications (Part 3)

COVID-19: Understanding the science & investment implications (Part 3)

A new video series from our healthcare team offers unique insight into the scientific and investment implications of the COVID-19 crisis.

Healthcare reform that could lower costs

Healthcare reform that could lower costs

Amid a raft of costly proposals to overhaul the US healthcare system, companies are hustling to find efficiencies and improve patient outcomes. Rich Carney, on the Global Life Sciences team alongside Andy Acker, discusses the innovations that may lead to lower costs and new sources of growth.

Healthcare reform that could lower costs

Healthcare reform that could lower costs

Amid a raft of costly proposals to overhaul the US healthcare system, companies are hustling to find efficiencies and improve patient outcomes. Rich Carney, on the Global Life Sciences team alongside Andy Acker, discusses the innovations that may lead to lower costs and new sources of growth.